{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field db970f54-9b35-4df0-aab9-a4f9e53f7eb5 --><h2>Co-amoxiclav</h2><!-- end field db970f54-9b35-4df0-aab9-a4f9e53f7eb5 -->","summary":"","htmlStringContent":"<!-- begin item 65ab7d66-5a9d-4a1a-b9c6-3d2dce73efd3 --><!-- end item 65ab7d66-5a9d-4a1a-b9c6-3d2dce73efd3 -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d939db08-52dc-5e24-89a9-20943ed35527","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 990cf897-a25e-44bb-89be-f359b7c17dc7 --><h3>What are the contraindications and cautions for co-amoxiclav?</h3><!-- end field 990cf897-a25e-44bb-89be-f359b7c17dc7 -->","summary":"","htmlStringContent":"<!-- begin item 02d1446a-7c80-47fe-b94a-267242e08618 --><!-- begin field 9b6586b8-d237-403b-8b1a-b5517785eb4b --><ul><li><strong>Do not prescribe </strong><strong>co-amoxiclav </strong>to people with:<ul><li>A <em>true </em>penicillin hypersensitivity. Gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li>A history of severe immediate hypersensitivity reaction to cephalosporins — there is some evidence of partial cross-allergenicity. </li><li>A history of co-amoxiclav- or penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution </strong>in people with:<ul><li>Hepatic impairment — monitor closely.</li><li>Chronic kidney disease (CKD) — reduce the dose of co-amoxiclav based on the estimated glomerular filtration rate (eGFR):<ul><li>If the eGFR is 10–30 mL/minute/1.73 m<sup>2</sup>, prescribe one 250/125 strength tablet every 12 hours <em>or </em>one 500/125 strength tablet every 12 hours.</li><li>If the eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, prescribe one 250/125 strength tablet every 24 hours <em>or </em>one 500/125 strength tablet every 24 hours.</li></ul></li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection, glandular fever — increased risk of erythematous rashes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 9b6586b8-d237-403b-8b1a-b5517785eb4b --><!-- end item 02d1446a-7c80-47fe-b94a-267242e08618 -->","subChapters":[]},{"id":"97c72e00-014f-5abe-b9c8-dbf3655b71c9","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e191f5ad-c955-44b5-ba26-b1ad807faa3a --><h3>What are the possible adverse effects of co-amoxiclav?</h3><!-- end field e191f5ad-c955-44b5-ba26-b1ad807faa3a -->","summary":"","htmlStringContent":"<!-- begin item 9d643fc7-052e-40a8-b9fe-a7efd84b0920 --><!-- begin field c37888be-8f38-472b-8e36-852e9ac9736c --><ul><li><strong>The most common adverse effects of co-amoxiclav include </strong>nausea, vomiting, increased risk of infections (for example fungal infection and vaginitis), and diarrhoea.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis (delayed or immediate) </strong>is a serious but rare adverse effect of co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Cholestatic jaundice</strong> can occur either during or shortly after the use of co-amoxiclav.<ul><li>Cholestatic jaundice is more common in people above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.</li></ul></li><li><strong>Other adverse effects of co-amoxiclav include:</strong><ul><li>Uncommon — dizziness, dyspepsia, and headache.</li><li>Frequency unknown — akathisia, aseptic meningitis, black hairy tongue, crystalluria, haemorrhagic colitis, and hypersensitivity vasculitis. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field c37888be-8f38-472b-8e36-852e9ac9736c --><!-- end item 9d643fc7-052e-40a8-b9fe-a7efd84b0920 -->","subChapters":[]},{"id":"bf5c8a14-dd9a-5393-a2a7-c4f337cbe3fd","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a196427c-7a12-478e-ba4a-47dc7f60c77b --><h3>What are the possible drug interactions of co-amoxiclav?</h3><!-- end field a196427c-7a12-478e-ba4a-47dc7f60c77b -->","summary":"","htmlStringContent":"<!-- begin item 34792c9a-bb0e-412c-8b2c-d636f9c2d07f --><!-- begin field 356aca44-9093-44a4-9693-25a755d21660 --><ul><li><strong>Possible drug interactions of co-amoxiclav include:</strong><ul><li>Allopurinol — be aware that concomitant use of allopurinol and co-amoxiclav may increase the incidence of skin rashes.<ul><li>Manufacturer advises to consider alternatives.</li></ul></li><li>Anticoagulants (for example warfarin) — penicillins potentially alter the anticoagulant effect of warfarin. <ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the anticoagulant dose may be necessary. </li></ul></li><li>Methotrexate — amoxicillin is predicted to increase the risk of toxicity when given with methotrexate.<ul><li>If concurrent treatment is indicated, monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li><li>Probenecid — the renal tubular secretion of amoxicilin is decreased by probenecid. Concurrent use may result in increased and prolonged blood levels of amoxicillin, but not of clavulanic acid.<ul><li>Manufacturer recommends avoiding concurrent use.</li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not </em>required during or after courses of penicillins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> <hyperlink-marker innertext=\"Contraception - combined hormonal methods\" refid=\"-494585\"></hyperlink-marker>and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 356aca44-9093-44a4-9693-25a755d21660 --><!-- end item 34792c9a-bb0e-412c-8b2c-d636f9c2d07f -->","subChapters":[]},{"id":"829bc8f7-4feb-5bac-abc0-760f30251e1a","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 844ffa17-8f1c-49a8-ab1d-b407d289f723 --><h3>Can co-amoxiclav be used during pregnancy and breastfeeding?</h3><!-- end field 844ffa17-8f1c-49a8-ab1d-b407d289f723 -->","summary":"","htmlStringContent":"<!-- begin item f610b6e1-ca84-40c0-9835-3d38fc506faf --><!-- begin field 1679ea2e-b9e5-4054-bc5a-44073570b3ed --><ul><li><strong>Pregnancy</strong><ul><li>Co-amoxiclav is not known to be harmful in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>].</li><li>The vast majority of the large amount of available data shows no increased risk of congenital malformation, spontaneous abortion, intrauterine death, low birth weight, preterm delivery, or neonatal complications following maternal exposure to therapeutic doses of penicillins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">UKTIS, 2017a</a>].</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Trace amounts of co-amoxiclav are found in breastmilk, but it is appropriate to use in women who are breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>].</li><li>Penicillins (and cephalosporins) are the antibiotics of choice in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Kearney, 2016</a>].</li></ul></li></ul><!-- end field 1679ea2e-b9e5-4054-bc5a-44073570b3ed --><!-- end item f610b6e1-ca84-40c0-9835-3d38fc506faf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}